Table 4.

Predictors of Outcome in Discovery Phase Lobar ICH Patients

LOBAR ICH MORTALITY (n = 409)
Univariate			Multivariate
Variable	OR (95% CI)	p-value	Variable	OR (95% CI)	p-value
Age	1·04 (1·03 – 1·05)	< 0·001	Age	1·08 (1·05 – 1·10)	< 0·001
Sex	0·76 (0·36 – 1·62)	0·48	Sex	0·73 (0·43 – 1·22)	0·23
HTN	1·22 (0·74 – 2·01)	0·45	HTN	1·08 (0·63 – 1·85)	0·79
Warfarin Use	2·27 (1·66 – 3·12)	< 0·001	Warfarin Use	2·51 (1·28 – 4·94)	0·007
Aspirin Use	0·96 (0·60 – 1·54)	0·88	Aspirin Use	0·91 (0·54 – 1·53)	0·73
APOE ε2	1·67 (1·15 – 2·43)	0·007	APOE ε2	1·60 (1·13 – 2·25)	0·008
APOE ε4	1·04 (0·65 – 1·66)	0·88	APOE ε4	1·18 (0·85 – 1·64)	0·10

LOBAR ICH POOR OUTCOME (n = 456)
Univariate			Multivariate
Variable	OR (95% CI)	p-value	Variable	OR (95% CI)	p-value
Age	1·07 (1·05 – 1·10)	< 0·001	Age	1·08 (1·05 – 1·10)	< 0·001
Sex	0·64 (0·40 – 1·02)	0·062	Sex	1·11 (0·70 – 1·72)	0·66
HTN	0·97 (0·63 – 1·50)	0·90	HTN	0·83 (0·52 – 1·33)	0·43
Warfarin Use	1·80 (1·12 – 2·90)	0·016	Warfarin Use	1·96 (1·18 – 3·27)	0·010
Aspirin Use	0·97 (0·65 – 1·45)	0·90	Aspirin Use	0·85 (0·55 – 1·33)	0·48
APOE ε2	1·68 (1·13 – 2·50)	0·007	APOE ε2	1·47 (1·10 – 2·0)	0·009
APOE ε4	1·18 (0·76 – 1·84)	0·37	APOE ε4	1·24 (0·83 – 1·85)	0·08

Both univariate and multivariate analysis are adjusted for Principal Components 1 and 2 to eliminate possible confounding due to population stratification.

95% CI = 95% Confidence Interval, HTN = History of Hypertension, OR = Odds Ratio